Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Shire

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.

Shire

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

Shire acquisition and Bristol-Myers Squibb’s $74bn Celgene takeover, after failing to reach terms with AstraZeneca a few years ago.

EMA sees approval numbers rise in 2018

EMA sees approval numbers rise in 2018 These were Roche’s Hemlibra, Shire’s Takhzyro, Alnylam’s Onpattro and Tegsedi. US shutdown and Brexit.

BMS and Celgene announce $74bn merger

BMS and Celgene announce $74bn merger The deal eclipses another big M&A deal, the $62bn takeover of Shire by Takeda, which began in 2018 and is expected to be formally completed with the next few days.

Takeda secures investor backing for £46bn Shire takeover

Takeda secures investor backing for £46bn Shire takeover Weber is adamant that Shire will help Takeda grow outside Japan, swelling the company’s pipeline in the process. ... Weber said: “We are delighted that our shareholders have given their strong support to our acquisition of Shire.

Shire’s angioedema drug Takhzyro claims EU approval

Shire’s angioedema drug Takhzyro claims EU approval Analysts have predicted that the drug could make up to $2bn in peak sales, making it one of the brightest prospects in Shire’s pipeline. ... It’s early US take-up is encouraging, according to Shire, with third quarter sales coming in at $51m.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics